PortalPublikationenPrevalence, characteristics and outcome of non-cardiac chest...

Prevalence, characteristics and outcome of non-cardiac chest pain and elevated Copeptin levels

Standard

Prevalence, characteristics and outcome of non-cardiac chest pain and elevated Copeptin levels. / Stallone, Fabio; Twerenbold, Raphael; Wildi, Karin; Reichlin, Tobias; Gimenez, Maria Rubini; Haaf, Philip; Fuechslin, Nicole; Hillinger, Petra; Jaeger, Cedric; Kreutzinger, Philipp; Puelacher, Christian; Radosavac, Milos; Weidmann, Zoraida Moreno; Moehring, Berit; Honegger, Ursina; Schumacher, Carmela; Denhaerynck, Kris; Arnold, Christiane; Bingisser, Roland; Vollert, Jörn Ole; Osswald, Stefan; Mueller, Christian.

in: HEART, Jahrgang 100, Nr. 21, 01.11.2014, S. 1708-1714.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Stallone, F, Twerenbold, R, Wildi, K, Reichlin, T, Gimenez, MR, Haaf, P, Fuechslin, N, Hillinger, P, Jaeger, C, Kreutzinger, P, Puelacher, C, Radosavac, M, Weidmann, ZM, Moehring, B, Honegger, U, Schumacher, C, Denhaerynck, K, Arnold, C, Bingisser, R, Vollert, JO, Osswald, S & Mueller, C 2014, 'Prevalence, characteristics and outcome of non-cardiac chest pain and elevated Copeptin levels', HEART, Jg. 100, Nr. 21, S. 1708-1714. https://doi.org/10.1136/heartjnl-2014-305583

APA

Stallone, F., Twerenbold, R., Wildi, K., Reichlin, T., Gimenez, M. R., Haaf, P., Fuechslin, N., Hillinger, P., Jaeger, C., Kreutzinger, P., Puelacher, C., Radosavac, M., Weidmann, Z. M., Moehring, B., Honegger, U., Schumacher, C., Denhaerynck, K., Arnold, C., Bingisser, R., ... Mueller, C. (2014). Prevalence, characteristics and outcome of non-cardiac chest pain and elevated Copeptin levels. HEART, 100(21), 1708-1714. https://doi.org/10.1136/heartjnl-2014-305583

Vancouver

Stallone F, Twerenbold R, Wildi K, Reichlin T, Gimenez MR, Haaf P et al. Prevalence, characteristics and outcome of non-cardiac chest pain and elevated Copeptin levels. HEART. 2014 Nov 1;100(21):1708-1714. https://doi.org/10.1136/heartjnl-2014-305583

Bibtex

@article{09c30f21ac204c0cbc2e31aa581c564c,
title = "Prevalence, characteristics and outcome of non-cardiac chest pain and elevated Copeptin levels",
abstract = "Objective: Copeptin, a quantitative marker of endogenous stress, seems to provide incremental value in addition to cardiac troponin in the early rule-out of acute myocardial infarction (AMI). Prevalence, characteristics and outcome of acute chest pain patients with causes other than AMI and elevated copeptin are poorly understood.Methods: A total of 984 consecutive patients with non-cardiac chest pain were selected from a prospective multicentre study of acute chest pain patients presenting to the emergency department. Levels of copeptin were determined in a blinded fashion and considered elevated if above 13 pmol/L (the 97,5th centile of healthy individuals). The final diagnosis was adjudicated by two independent cardiologists. Median duration of follow-up was 756 days.Results: Elevated copeptin levels were seen in 215 patients (22%). In comparison to patients with normal copeptin levels, patients with elevated levels were older, had more pre-existing cardiac and non-cardiac disorders, more silent cardiomyocyte injury and increased haemodynamic stress as quantified by levels of highsensitivity cardiac troponin T (9.6 ng/L (3.6-18.3) vs 5.8 ng/L (2.9-9.4)) and B-type natriuretic peptide (75 ng/L (37-187) vs 35 ng/L (15-77)) (both p<0.001), more electrocardiographic abnormalities, more often an adjudicated diagnosis of gastroesophageal reflux or bronchitis/pneumonia and higher 2-year mortality (HR 2.9, 95% CI 1.5 to 5.7). The increased mortality rate seemed to be largely explained by age and comorbidities.Conclusions: Elevated levels of copeptin are present in about one in five patients with non-cardiac chest pain and are associated with aging, cardiac and non-cardiac comorbidities as well as mortality.",
author = "Fabio Stallone and Raphael Twerenbold and Karin Wildi and Tobias Reichlin and Gimenez, {Maria Rubini} and Philip Haaf and Nicole Fuechslin and Petra Hillinger and Cedric Jaeger and Philipp Kreutzinger and Christian Puelacher and Milos Radosavac and Weidmann, {Zoraida Moreno} and Berit Moehring and Ursina Honegger and Carmela Schumacher and Kris Denhaerynck and Christiane Arnold and Roland Bingisser and Vollert, {J{\"o}rn Ole} and Stefan Osswald and Christian Mueller",
year = "2014",
month = nov,
day = "1",
doi = "10.1136/heartjnl-2014-305583",
language = "English",
volume = "100",
pages = "1708--1714",
journal = "HEART",
issn = "1355-6037",
publisher = "BMJ PUBLISHING GROUP",
number = "21",

}

RIS

TY - JOUR

T1 - Prevalence, characteristics and outcome of non-cardiac chest pain and elevated Copeptin levels

AU - Stallone, Fabio

AU - Twerenbold, Raphael

AU - Wildi, Karin

AU - Reichlin, Tobias

AU - Gimenez, Maria Rubini

AU - Haaf, Philip

AU - Fuechslin, Nicole

AU - Hillinger, Petra

AU - Jaeger, Cedric

AU - Kreutzinger, Philipp

AU - Puelacher, Christian

AU - Radosavac, Milos

AU - Weidmann, Zoraida Moreno

AU - Moehring, Berit

AU - Honegger, Ursina

AU - Schumacher, Carmela

AU - Denhaerynck, Kris

AU - Arnold, Christiane

AU - Bingisser, Roland

AU - Vollert, Jörn Ole

AU - Osswald, Stefan

AU - Mueller, Christian

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Objective: Copeptin, a quantitative marker of endogenous stress, seems to provide incremental value in addition to cardiac troponin in the early rule-out of acute myocardial infarction (AMI). Prevalence, characteristics and outcome of acute chest pain patients with causes other than AMI and elevated copeptin are poorly understood.Methods: A total of 984 consecutive patients with non-cardiac chest pain were selected from a prospective multicentre study of acute chest pain patients presenting to the emergency department. Levels of copeptin were determined in a blinded fashion and considered elevated if above 13 pmol/L (the 97,5th centile of healthy individuals). The final diagnosis was adjudicated by two independent cardiologists. Median duration of follow-up was 756 days.Results: Elevated copeptin levels were seen in 215 patients (22%). In comparison to patients with normal copeptin levels, patients with elevated levels were older, had more pre-existing cardiac and non-cardiac disorders, more silent cardiomyocyte injury and increased haemodynamic stress as quantified by levels of highsensitivity cardiac troponin T (9.6 ng/L (3.6-18.3) vs 5.8 ng/L (2.9-9.4)) and B-type natriuretic peptide (75 ng/L (37-187) vs 35 ng/L (15-77)) (both p<0.001), more electrocardiographic abnormalities, more often an adjudicated diagnosis of gastroesophageal reflux or bronchitis/pneumonia and higher 2-year mortality (HR 2.9, 95% CI 1.5 to 5.7). The increased mortality rate seemed to be largely explained by age and comorbidities.Conclusions: Elevated levels of copeptin are present in about one in five patients with non-cardiac chest pain and are associated with aging, cardiac and non-cardiac comorbidities as well as mortality.

AB - Objective: Copeptin, a quantitative marker of endogenous stress, seems to provide incremental value in addition to cardiac troponin in the early rule-out of acute myocardial infarction (AMI). Prevalence, characteristics and outcome of acute chest pain patients with causes other than AMI and elevated copeptin are poorly understood.Methods: A total of 984 consecutive patients with non-cardiac chest pain were selected from a prospective multicentre study of acute chest pain patients presenting to the emergency department. Levels of copeptin were determined in a blinded fashion and considered elevated if above 13 pmol/L (the 97,5th centile of healthy individuals). The final diagnosis was adjudicated by two independent cardiologists. Median duration of follow-up was 756 days.Results: Elevated copeptin levels were seen in 215 patients (22%). In comparison to patients with normal copeptin levels, patients with elevated levels were older, had more pre-existing cardiac and non-cardiac disorders, more silent cardiomyocyte injury and increased haemodynamic stress as quantified by levels of highsensitivity cardiac troponin T (9.6 ng/L (3.6-18.3) vs 5.8 ng/L (2.9-9.4)) and B-type natriuretic peptide (75 ng/L (37-187) vs 35 ng/L (15-77)) (both p<0.001), more electrocardiographic abnormalities, more often an adjudicated diagnosis of gastroesophageal reflux or bronchitis/pneumonia and higher 2-year mortality (HR 2.9, 95% CI 1.5 to 5.7). The increased mortality rate seemed to be largely explained by age and comorbidities.Conclusions: Elevated levels of copeptin are present in about one in five patients with non-cardiac chest pain and are associated with aging, cardiac and non-cardiac comorbidities as well as mortality.

UR - http://www.scopus.com/inward/record.url?scp=84922061403&partnerID=8YFLogxK

U2 - 10.1136/heartjnl-2014-305583

DO - 10.1136/heartjnl-2014-305583

M3 - SCORING: Journal article

C2 - 24968886

AN - SCOPUS:84922061403

VL - 100

SP - 1708

EP - 1714

JO - HEART

JF - HEART

SN - 1355-6037

IS - 21

ER -